Common Contracts
5 similar Employment Agreement contracts by Stoke Therapeutics, Inc.
Edward Kaye, M.D. [ADDRESS]Employment Agreement • May 23rd, 2019 • Stoke Therapeutics, Inc. • Pharmaceutical preparations • Delaware
On behalf of Stoke Therapeutics, Inc. (the “Company”), this letter agreement (the “Agreement”) sets forth the terms and conditions of your appointment as the Company’s Chief Executive Officer, effective as of October 17, 2017 (the “Employment Date”).
September 8, 2017 Barry Ticho, M.D., Ph.D. Newton, MAEmployment Agreement • May 23rd, 2019 • Stoke Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
On behalf of Stoke Therapeutics, Inc. (the “Company”), this letter agreement (the “Agreement”) sets forth the terms and conditions of your appointment as the Company’s Chief Medical Officer, effective as of October 2, 2017 (the “Employment Date”).
February 12, 2019 Stephen Tulipano Stoneham, MA 02180Employment Agreement • May 23rd, 2019 • Stoke Therapeutics, Inc. • Pharmaceutical preparations • Delaware
On behalf of Stoke Therapeutics, Inc. (the “Company”), this letter agreement (the “Agreement”) sets forth the terms and conditions of your appointment as the Company’s Chief Financial Officer, effective as of March 18, 2019 (the “Employment Date”).
November 20, 2015 Huw M. Nash, Ph.D. Lexington, MA 02421Employment Agreement • May 23rd, 2019 • Stoke Therapeutics, Inc. • Pharmaceutical preparations • New York
On behalf of ASOthera Pharmaceuticals, Inc. (the “Company”), this letter agreement (the “Agreement”) sets forth the terms and conditions of your appointment as the Chief Executive Officer of the Company, effective as of October 24, 2014 (the “Employment Date”).
January 7, 2018 Gene Liau, Ph.D. Wayland, MA 01778Employment Agreement • May 23rd, 2019 • Stoke Therapeutics, Inc. • Pharmaceutical preparations • Delaware
On behalf of Stoke Therapeutics, Inc. (the “Company”), this letter agreement (the “Agreement”) sets forth the terms and conditions of your appointment as the Company’s Executive Vice President, Head of Research and Preclinical Development, effective as of January 16, 2018 (the “Employment Date”).
